최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기Annals of surgical oncology, v.24 no.8, 2017년, pp.2174 - 2181
Song, Bong-Il , Kim, Hae Won , Won, Kyoung Sook
Conclusions. Combining the pSUV(max) of each molecular subtype with the nodal F-18-FDG uptake finding can improve the prediction of ALN metastasis in IDC....
American Cancer Society 2016 Cancer Facts & Figures 2016 American Cancer Society. Cancer Facts & Figures 2016. American Cancer Society, Atlanta, 2016.
J Clin Oncol M Banerjee 22 2567 2004 10.1200/JCO.2004.11.141 Banerjee M, George J, Song EY, Roy A, Hryniuk W. Tree-based model for breast cancer prognostication. J Clin Oncol. 2004;22:2567-75.
Eur J Radiol R Lavayssière 69 50 2009 10.1016/j.ejrad.2008.07.039 Lavayssière R, Cabée A-E, Filmont J-E. Positron emission tomography (PET) and breast cancer in clinical practice. Eur J Radiol. 2009;69:50-8.
A meta-analysis. Breast Cancer Res Treat Y Wang 131 357 2012 10.1007/s10549-011-1780-z Wang Y, Zhang C, Liu J, Huang G. Is 18F-FDG PET accurate to predict neoadjuvant therapy response in breast cancer? A meta-analysis. Breast Cancer Res Treat. 2012;131:357-69.
Ann Surg Oncol V Dialani 22 1416 2015 10.1245/s10434-015-4403-9 Dialani V, Chadashvili T, Slanetz PJ. Role of imaging in neoadjuvant therapy for breast cancer. Ann Surg Oncol. 2015;22:1416-24.
J Clin Oncol RL Wahl 22 277 2003 10.1200/JCO.2004.04.148 Wahl RL. Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET study group. J Clin Oncol. 2003;22:277-85.
Ann Oncol U Veronesi 18 473 2006 10.1093/annonc/mdl425 Veronesi U, De Cicco C, Galimberti V, Fernandez JR, Rotmensz N, Viale G et al. A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases. Ann Oncol. 2006;18:473-8.
Eur J Nucl Med Mol Imaging TA Heusner 36 1543 2009 10.1007/s00259-009-1145-6 Heusner TA, Kuemmel S, Hahn S, Koeninger A, Otterbach F, Hamami ME, et al. Diagnostic value of full-dose FDG PET/CT for axillary lymph node staging in breast cancer patients. Eur J Nucl Med Mol Imaging. 2009;36:1543-50.
J Clin Oncol KI Pritchard 30 1274 2012 10.1200/JCO.2011.38.1103 Pritchard KI, Julian JA, Holloway CMB, McCready D, Gulenchyn KY, George R, et al. Prospective study of 2-[18F]fluorodeoxyglucose positron emission tomography in the assessment of regional nodal spread of disease in patients with breast cancer: an Ontario clinical oncology group study. J Clin Oncol. 2012;30:1274-9.
PLoS ONE. J Jung 10 e0144152 2015 10.1371/journal.pone.0144152 Jung J, Kim C-Y, Son SH, Kim DH, Jeong SY, Lee SW, et al. Preoperative prediction of cervical lymph node metastasis using primary tumor SUVmax on 18F-FDG PET/CT in patients with papillary thyroid carcinoma. PLoS ONE. 2015;10:e0144152.
Eur J Nucl Med Mol Imaging. D-H Kim 41 2051 2014 10.1007/s00259-014-2831-6 Kim D-H, Song B-I, Hong CM, Jeong SY, Lee SW, Lee J, et al. Metabolic parameters using 18F-FDG PET/CT correlate with occult lymph node metastasis in squamous cell lung carcinoma. Eur J Nucl Med Mol Imaging. 2014;41:2051-7.
J Thorac Cardiovasc Surg. Y Tsutani 144 1365 2012 10.1016/j.jtcvs.2012.07.012 Tsutani Y, Miyata Y, Nakayama H, Okumura S, Adachi S, Yoshimura M, et al. Prediction of pathologic node-negative clinical stage IA lung adenocarcinoma for optimal candidates undergoing sublobar resection. J Thorac Cardiovasc Surg. 2012;144:1365-71.
Breast Cancer. NY Jung 23 712 2016 10.1007/s12282-015-0629-4 Jung NY, Kim SH, Kang BJ, Park SY, Chung MH. The value of primary tumor 18F-FDG uptake on preoperative PET/CT for predicting intratumoral lymphatic invasion and axillary nodal metastasis. Breast Cancer. 2016;23:712-7.
Eur Radiol. JY Kim 25 1172 2015 10.1007/s00330-014-3452-y Kim JY, Lee SH, Kim S, Kang T, Bae YT. Tumor 18 F-FDG uptake on preoperative PET/CT may predict axillary lymph node metastasis in ER-positive/HER2-negative and HER2-positive breast cancer subtypes. Eur Radiol. 2015;25:1172-81.
J Nucl Med. SH Moon 55 743 2014 10.2967/jnumed.113.130716 Moon SH, Kim HS, Hyun SH, Choi YS, Zo JI, Shim YM, et al. Prediction of occult lymph node metastasis by metabolic parameters in patients with clinically N0 esophageal squamous cell carcinoma. J Nucl Med. 2014;55:743-8.
J Nucl Med. A Mavi 48 1266 2007 10.2967/jnumed.106.037440 Mavi A, Cermik TF, Urhan M, Puskulcu H, Basu S, Jian QY, et al. The effects of estrogen, progesterone, and C-erbB-2 receptor states on 18F-FDG uptake of primary breast cancer lesions. J Nucl Med. 2007;48:1266-72.
Eur J Nucl Med Mol Imaging. K Kitajima 42 1371 2015 10.1007/s00259-015-3070-1 Kitajima K, Fukushima K, Miyoshi Y, Nishimukai A, Hirota S, Igarashi Y, et al. Association between 18F-FDG uptake and molecular subtype of breast cancer. Eur J Nucl Med Mol Imaging. 2015;42:1371-7.
Eur J Nucl Med Mol Imaging. AM García Vicente 40 1304 2013 10.1007/s00259-013-2418-7 García Vicente AM, Soriano Castrejón Á, León Martín A, López-Muñiz IC, Madero VM, Sánchez MD, et al. Molecular subtypes of breast cancer: metabolic correlation with 18F-FDG PET/CT. Eur J Nucl Med Mol Imaging. 2013;40:1304-11.
Arch Pathol Lab Med. AC Wolff 131 18 2007 10.5858/2007-131-18-ASOCCO Wolff AC, Hammond MEH, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2007;131:18-43.
Ann Oncol. A Goldhirsch 22 1736 2011 10.1093/annonc/mdr304 Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ, et al. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22:1736-47.
J Clin Oncol. NC Hodgson 26 712 2008 10.1200/JCO.2007.13.8412 Hodgson NC, Gulenchyn KY. Is there a role for positron emission tomography in breast cancer staging? J Clin Oncol. 2008;26:712-20.
Clin Breast Cancer. SJ Crabb 8 249 2008 10.3816/CBC.2008.n.028 Crabb SJ, Cheang MCU, Leung S, Immonen T, Nielsen TO, Huntsman DD, et al. Basal breast cancer molecular subtype predicts for lower incidence of axillary lymph node metastases in primary breast cancer. Clin Breast Cancer. 2008;8:249-56.
Medicine Baltimore. Z-Y He 94 e2213 2015 10.1097/MD.0000000000002213 He Z-Y, Wu S-G, Yang Q, Sun JY, Li FY, Lin Q, et al. Breast cancer subtype is associated with axillary lymph node metastasis: a retrospective cohort study. Medicine Baltimore. 2015;94:e2213.
J Nucl Med. JW Fletcher 49 480 2008 10.2967/jnumed.107.047787 Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH, et al. Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med. 2008;49:480-508.
J Nucl Med. D Groheux 57 17S 2016 10.2967/jnumed.115.157859 Groheux D, Cochet A, Humbert O, Alberini J-L, Hindie E, Mankoff D. 18F-FDG PET/CT for staging and restaging of breast cancer. J Nucl Med. 2016;57:17S-26S.
Cancer. M Oshida 82 2227 1998 10.1002/(SICI)1097-0142(19980601)82:11<2227::AID-CNCR18>3.0.CO;2-W Oshida M, Uno K, Suzuki M, Nagashima T, Hashimoto H, Yagata H, et al. Predicting the prognoses of breast carcinoma patients with positron emission tomography using 2-deoxy-2-fluoro[18F]-d-glucose. Cancer. 1998;82:2227-34.
J Clin Oncol. GH Lyman 23 7703 2005 10.1200/JCO.2005.08.001 Lyman GH, Giuliano AE, Somerfield MR, Benson III AB, Bodurka DC, Burstein HJ, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early stage breast cancer. J Clin Oncol. 2005;23:7703-20.
J Nucl Med. M Soret 48 932 2007 10.2967/jnumed.106.035774 Soret M, Bacharach SL, Buvat I. Partial-volume effect in PET tumor imaging. J Nucl Med. 2007;48:932-45.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.